Table 4 Proportion of variance explained in the QoL parameters by each of the demographic and clinical variables for the boost groups (IORT-EBRT, IORTboost, and EBRTboost; results from univariate linear regression analyses)
| Â | Global health status | Restrictions in daily activities | General pain | Breast symptoms | Arm symptoms |
|---|---|---|---|---|---|
Age | 3,1%* | 2,1% | 4,5%* | 1% | 0,0% |
Married/partnered | 0,9% | 1,6% | 1,1% | 0,6% | 0,3% |
Employed | 2,4% | 3,7%* | 4,8%* | 0,0% | 0,7% |
Months since BCS | 2,6%* | 1,2% | 0,3% | 1,4% | 0,8% |
Tumor size | 1,3% | 0,5% | 0,8% | 0,2% | 0,2% |
Nodal involvement | 0,6% | 0,3% | 1,3% | 1,3% | 0,3% |
ALND | 1,0% | 0,0% | 0,0% | 0,8% | 0,0% |
Chemotherapy | 3,4%* | 3,3%* | 4,5%* | 0,3% | 0,2% |
Endocrine therapy | 0,0% | 0,2% | 0,0% | 0,7% | 0,1% |
Radiotherapy of supra- and infraclavicular nodes | 1,0% | 0,0% | 0,2% | 0,6% | 0,1% |
Medical comorbidities ≥2 | 15,0%** | 11,0%** | 17,7%** | 0,0% | 4,9%* |